Radiant Biotherapeutics

Radiants MultabodyTM platform enables multi-valent, multi-specific antibodies that have the potential to transform the treatment of cancer, inflammation, infections and other heterogeneous diseases. This breakthrough in antibody engineering combines avidity superior binding power with multi-specificity to create multifunctional biologics with the potential to unlock biology not achievable with current antibodies. Multabodies are a new class of biologics built on a modular, fully human scaffold, simplifying development while leveraging existing antibody manufacturing processes. We are rapidly advancing this superior next-generation therapeutic platform for a variety of indications. Learn more at radiantbio.com

Biotechnology,antibody,biologics,oncology,inflammation,antibodies,drugdiscovery,and canadianbiotech

Radiant biotherapeutics operates in the Biotechnology research industry.

Radiant biotherapeutics's revenue is 11m - 100m

Radiant biotherapeutics has 11 - 50 employees.